drugset / Trial / NCT05570188
Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
It is a single-center, open-labeled, single-arm, non-randomized investigator-initiated trial evaluating the efficacy and safety of anti-CD19 U-CAR-NK Cells Therapy combined with HSCT for B cell hematologic malignancies.
Timeline
- Start
- 2022-10-01
- Primary completion
- 2024-10-31
- Completion
- 2025-10-31
Outcome
Outcome not reported
Stopped: “The PI decides to stop.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD19 UCAR-NK cells | Cell therapy | 5e+06 cells/kg | — |
| Subject | Anti-CD19 UCAR-NK cells | Cell therapy | 1e+07 cells/kg | — |
| Subject | Anti-CD19 UCAR-NK cells | Cell therapy | 2e+07 cells/kg | — |
| Subject | Anti-CD19 UCAR-NK cells | Cell therapy | 5e+07 cells/kg | — |